BERLIN, GERMANY, May 23, 2019 – Myocardial Solutions provided MyoStrain® cardiac function exams to attendees of the 2019 Hauptstadt Congress for Medicine and Health (Hauptstadt Kongress) in Berlin, Germany from Mary 21st – 23rd. In collaboration with medneo GmbH, Berlin Heart Institute and Philips, MyoStrain provided scan demonstrations to 59 participants attending the event. Using medneo’s mobile imaging truck on Philips’ T1.5 MRI machines, all scans were completed over the 2.5 day event, yielding, on average, 10-minute exam times per patient scanned. All MyoStrain scan slots were booked during the first day of the event.
Prof. Sebastian Kelle and his cardiology colleagues from the Berlin Heart Institute reviewed MyoStrain results with patients. Prof. Kelle commented: “The Congress has been very successful in creating awareness for MyoStrain, which could become the new standard in cardiac function testing in patients with risks of heart failure. It’s speed, ease and accuracy makes the test very patient-centric. Patients want to have an accurate functional assessment of their heart.”
Referred to as the “Davos of Medicine” in Germany, Capital Congress is a major event for the foremost figures and decision makers in Germany’s health care system. Health care industry leaders came from across the country to discuss changes in health care policy and new developments in medical priorities. Attendees included government officials and CEOs of health insurance companies, pharmaceutical firms and hospital systems.
Matt Mittino, General Manager of Myocardial Solutions – Europe, said: “The purpose of MyoStrain testing is to quantify cardiac function and is sensitive enough to detect sub-clinical problems (before symptoms). With early detection of heart dysfunction, physicians can provide early treatment to hopefully avoid adverse events. We are positioning MyoStrain as a cardiac health prevention tool that should provide significant healthcare system cost savings in addition to better patient care.”
Following the event, André Glardon, Founder of medneo, had this to say: “For medneo, MyoStrain and Philips, this Congress has demonstrated the patient demand for rapid cardiac magnetic resonance testing that can accurately assess cardiac function. The Congress has asked us to return next year and set up the truck inside the Congress. We have also found high interest in providing mobile technologies across the country.”
About Myocardial Solutions, Inc.
Myocardial Solutions, Inc. (MSI) is a medical technology company working to transform the cardiac and cancer care continuum. Leveraging more than 400 publications in clinical research and development, MSI’s proprietary technology, MyoStrain®, is a 10-minute, non-invasive heart function test providing physicians with sensitive diagnostic markers to support the early assessment and individualized treatment of heart dysfunction. MyoStrain has received FDA-510(k) pre-market clearance, CE-mark certification, and is commercially available in the United States and Europe.
To learn more about MyoStrain, visit myocardialsolutions.com or connect with us on LinkedIn and Twitter @myocardialsoln.